Although the application of FAP-IL-2 has been reported to stimulate effector cells in the periphery [6] as well, the fusion of IL-2v to the anti-FAP Ab was performed to preferentially transport an additional stimulating agent (IL-2v) into the tumor tissue. This evidence concerns the gene IL2 and neoplasm.